The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology
A number of industries performed per trial was significantly larger for the industry. Claims of subgroup effect were made in 52% of trials and 50% in CA. Only 25% of interaction evident in only 25%.

Related Post